Network Meta-Analysis of Tofacitinib, Biologic Disease-Modifying Antirheumatic Drugs, and Apremilast for the Treatment of Psoriatic Arthritis

BACKGROUND: Tofacitinib and other new treatments approved for use in psoriatic arthritis have only recently been included in psoriatic arthritis treatment guidelines, and studies evaluating the relative efficacy of available therapies are important to inform treatment decisions by healthcare profess...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Curr Ther Res Clin Exp
Egile Nagusiak: Gladman, Dafna D., Orbai, Ana-Maria, Gomez-Reino, Juan, Chang-Douglass, Stacey, Leoncini, Emanuele, Burton, Hannah E., Kanik, Keith S., Romero, Ana Belen, Cappelleri, Joseph C., Hsu, Ming-Ann
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Elsevier 2020
Gaiak:
Original Research
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC7494680/
https://ncbi.nlm.nih.gov/pubmed/32983284
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.curtheres.2020.100601
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak